News
Eli Lilly sues four telehealth compounding GLP-1 companies
Eli Lilly is suing four telehealth companies that prescribe compounded versions of the pharmaceutical company's weight loss medications. Lilly filed four lawsuits on Wednesday claiming telehealth companies were misleading consumers and illegally prescribing compounded versions of its glucagon-like peptide-1 agonist drugs Mounjaro and Zepbound.
1don MSN
We recently published a list of Jim Cramer Says Trump’s Fed Chair Tussle Is Like “The Godfather” & Discusses These 10 Stocks.
shares surge Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of diabetes patients, and the company said it expects to seek ...
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix ...
Eli Lilly (LLY) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced success Thursday of its Phase 3 clinical trial for a once-daily GLP-1 pill — an oral form of the blockbuster medication used for ...
Eli Lilly and Company is shifting away from using horseshoe crabs, specifically their blood that’s used to detect dangerous bacterial toxins, to now using a synthetic alternative. “We test ...
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call that day with the investment community and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback